leadf
logo-loader
viewLondon Stock Exchange Group PLC

London Stock Exchange does not plan to sell Borsa Italiana subsidiary after Refinitiv deal: newspaper

Il Sole 24 Ore said Borsa Italiana unit CEO Raffaele Jerusalmi told it that the LSE considers the Italian exchange operator a strategic subsidiary

Milan
Italian newspapers have speculated that Borsa Italiana could be a target for European stock market operator Euronext

London Stock Exchange Group PLC (LON:LSE) saw its shares rise modestly on Friday after an Italian newspaper reported that the firm does not plan to sell its Borsa Italiana subsidiary after its $27 billion deal to buy data provider Refinitiv.

Newspaper Il Sole 24 Ore said LSE board member and Borsa Italiana unit CEO Raffaele Jerusalmi told it that the FTSE 100-listed firm considers the Italian exchange operator to be a strategic subsidiary.

The move to acquire Refinitiv, confirmed last month, has inevitably triggered speculation about the possible sale of assets to gain anti-trust approval and to fund the deal.

Italian newspapers have speculated that Borsa Italiana could be a target for European stock market operator Euronext.

However, Jerusalmi told Il Sole: “Euronext repeatedly said it was interested in having Borsa Italiana in its network, but Borsa Italiana is not up for sale.”

He added: “Borsa Italiana is a strategic asset for the London Stock Exchange group, which wants to keep investing in Italy.”

In afternoon trade on Friday, LSE shares were 0.9% higher at 7,750p.

Quick facts: London Stock Exchange Group PLC

Price: 8516 GBX

LSE:LSE
Market: LSE
Market Cap: £29.93 billion
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

4D pharma plc merges with SPAC company Longevity Acquisition Corp

4D pharma plc (LON:DDDD) CEO Duncan Peyton tells Proactive the group is to get a cash injection of US$14.6mln through a merger with Longevity Acquisition Corporation (NASDAQ:LOAC), a special purpose acquisition company. Peyton says the merger will accelerate and de-risk 4D's admission to...

56 minutes ago

2 min read